The company announced today that it has secured product patents in ARIPO (AP 3340), Europe (2611444), Hong Kong (HK1187613), Japan (5805795) Macau (J/001756 & J/001848) and South Korea (10-1554407) to their New Chemical Entities (NCE’s) for CNS therapy through mechanism of action – H3 Inverse agonist and these patents are valid until 2031.
The company announced today that it has secured product patents in ARIPO (AP 3340), Europe (2611444), Hong Kong (HK1187613), Japan (5805795) Macau (J/001756 & J/001848) and South Korea (10-1554407) to their New Chemical Entities (NCE’s) for CNS therapy through mechanism of action – H3 Inverse agonist and these patents are valid until 2031. The granted claims of the patent include the class of selective H3 ligands discovered by Suven and are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neurodegenerative disorders.
With these new patents, Suven has a total of 1 granted product patent in ARIPO, 19 granted patents from Europe, 18 granted patents from Hong Kong, 18 granted patents from Japan, 7 granted patents from Macau and 18 granted patents from South Korea. These granted patents are exclusive intellectual property of Suven and are achieved through the internal discovery research efforts. Products out of these inventions may be out-licensed at various phases of clinical development like at Phase-I or Phase-II.
“We are very pleased by the grant of these patents to Suven for our pipeline of molecules in CNS arena that are being developed for cognitive disorders with high unmet medical need with huge market potential globally” says Venkat Jasti, CEO of Suven.
No comments:
Post a Comment